PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling

Blood

Volumn 112, Issue 10, 2008, Pages 4098-4108

  Lu, Xiaoqing ^a   Malumbres, Raquel ^a   Shields, Benjamin ^b   Jiang, Xiaoyu ^a   Sarosiek, Kristopher A ^a   Natkunam, Yasodha ^c   Tiganis, Tony ^b   Lossos, Izidore S ^a,d  

^a UNIVERSITY OF MIAMI   (United States)

^b MONASH UNIVERSITY   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; JANUS KINASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; STAT6 PROTEIN; STAUROSPORINE; ENZYME INHIBITOR; IL4 PROTEIN, HUMAN; PROTEIN KINASE TYK2; PTPN1 PROTEIN, HUMAN; PTPN1 PROTEIN, MOUSE; STAT5 PROTEIN; STAT5A PROTEIN, HUMAN; STAT5A PROTEIN, MOUSE; STAT5B PROTEIN, HUMAN; STAT5B PROTEIN, MOUSE; STAT6 PROTEIN, HUMAN; STAT6 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN; TYK2 PROTEIN, HUMAN; TYK2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CONTROLLED STUDY; EMBRYO; ENZYME SUBSTRATE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; IMMUNOLOGY; LARGE CELL LYMPHOMA; METABOLISM; MISSENSE MUTATION; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-4; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; STAUROSPORINE; TUMOR SUPPRESSOR PROTEINS; TYK2 KINASE;

EID: 58149148417     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-148726     Document Type: Article

References (50)

1. Nelms K, Huang H, Ryan J, Keegan A, Paul WE. Interleukin-4 receptor signalling mechanisms and their biological significance. Adv Exp Med Biol. 1998;452:37-43.
2. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991;77:1859-1870.
3. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
4. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest. 1993;91:88-93.
5. Schwarz MA, Tardelli L, Macosko HD, Sullivan LM, Narula SK, Fine JS. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 1995;55:3692-3696.
6. Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res. 1995;55:2173-2176.
7. Lu X, Nechushtan H, Ding F, et al. Distinct IL-4 induced gene expression, proliferation and intracellular signaling in germinal center B-cell like and activated B-cell like diffuse large cell lymphomas. Blood. 2004;105:2924-2932.
8. Nechushtan H, Rosenblatt JD, Lossos IS. IL-4 affects proliferation, chemosensitivity and rituximab sensitivity of germinal center B-cell like (GCB) and activated B-cell like (ABC) diffuse large B-Cell lymphoma differently. Blood. 2004; 104:73a.
9. Canfield S, Lee Y, Schroder A, Rothman P. Cutting edge: IL-4 induces suppressor of cytokine signaling-3 expression in B cells by a mechanism dependent on activation of p38 MAPK. J Immunol. 2005;174:2494-2498.
10. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900-911.
11. Lu X, Chen J, Sasmono RT, et al. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol. 2007;27:2166-2179.
12. Nakahira M, Tanaka T, Robson BE, Mizgerd JP, Grusby MJ. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity. 2007;26:163- 176.
13. Hanson EM, Dickensheets H, Qu CK, Donnelly RP, Keegan AD. Regulation of the dephosphorylation of Stat6: participation of Tyr-713 in the interleukin- 4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem. 2003;278:3903-3911.
14. Simoncic PD, McGlade CJ, Tremblay ML. PTP1B and TC-PTP: novel roles in immune-cell signaling. Can J Physiol Pharmacol. 2006;84:667-675.
15. Aoki N, Matsuda T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem. 2000;275:39718- 39726.
16. Myers MP, Andersen JN, Cheng A, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001;276:47771- 47774.
17. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood. 2003;101:433-440.
18. Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7: 445-455.
19. Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem. 2003;278:739-744.
20. Tiganis T, Bennett AM, Ravichandran KS, Tonks NK. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol Cell Biol. 1998;18:1622-1634.
21. Garton AJ, Flint AJ, Tonks NK. Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST. Mol Cell Biol. 1996;16:6408-6418.
22. Mikita T, Campbell D, Wu P, Williamson K, Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol. 1996;16:5811- 5820.
23. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003;17:789-795.
24. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood. 2005;105:3979- 3986.
25. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26:447- 454.
26. Tiganis T, Bennett AM. Protein tyrosine phosphatase function: the substrate perspective. Biochem J. 2007;402:1-15.
27. Flint AJ, Tiganis T, Barford D, Tonks NK. Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci U S A. 1997;94: 1680-1685.
28. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 2002;22:5662- 5668.
29. Kotanides H, Reich NC. Interleukin-4-induced STAT6 recognizes and activates a target site in the promoter of the interleukin-4 receptor gene. J Biol Chem. 1996;271:25555-25561.
30. Kenner KA, Anyanwu E, Olefsky JM, Kusari J. Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor- I-stimulated signaling. J Biol Chem. 1996;271: 19810-19816.
31. Walchli S, Curchod ML, Gobert RP, Arkinstall S, Hooft van Huijsduijnen R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor: a brute force approach based on "substrate-trapping" mutants. J Biol Chem. 2000; 275:9792-9796.
32. Buckley DA, Cheng A, Kiely PA, Tremblay ML, O'Connor R. Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1Bdeficient fibroblasts. Mol Cell Biol. 2002;22: 1998-2010.
33. Heinonen KM, Dube N, Bourdeau A, Lapp WS, Tremblay ML. Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling. Proc Natl Acad Sci U S A. 2006;103:2776-2781.
34. Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science. 2002;295:1708- 1711.
35. Gu F, Dube N, Kim JW, et al. Protein tyrosine phosphatase 1B attenuates growth hormonemediated JAK2-STAT signaling. Mol Cell Biol. 2003;23:3753-3762.
36. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002; 2:497-503.
37. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol. 2002;12:446- 453.
38. Aoki N, Matsuda T. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol. 2002; 16:58-69.
39. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol. 2005;25:819-829.
40. Liu F, Hill DE, Chernoff J. Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the Src homology 3 domain of p130(Cas). J Biol Chem. 1996;271:31290- 31295.
41. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein- tyrosine phosphatase 1B: possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem. 2000;275: 4283-4289.
42. Li S, Depetris RS, Barford D, Chernoff J, Hubbard SR. Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase. Structure. 2005;13:1643- 1651.
43. Fukada T, Tonks NK. Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling. EMBO J. 2003;22:479-493.
44. Fukada T, Tonks NK. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein- tyrosine kinase. J Biol Chem. 2001;276: 25512-25519.
45. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007;6:307- 319.
46. Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB. Protein tyrosine phosphatase 1B (PTP1B) expression is induced by inflammation in vivo. J Biol Chem. 2008;283: 14230-14241.
47. Dube N, Bourdeau A, Heinonen KM, Cheng A, Loy AL, Tremblay ML. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res. 2005; 65:10088-10095.
48. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature. 2000;403:503-511.
49. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
50. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.